Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.69 |
| ▸ | ACHE | P22303 | 3/20 | 0.69 |
| ▸ | FAAH | O00519 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.69 |
| ▸ | PDE5A | O76074 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | APP | P05067 | 1/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.69 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.69 |
| ▸ | DRD4 | P21917 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 1/20 | 0.69 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676837 | 1.00 | BCHE (0.69) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL6867659 | 1.00 | BCHE (0.69) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL678139 | 1.00 | BCHE (0.69) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL8281051 | 0.93 | BCHE (0.66) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL12808576 | 0.90 | ACHE (0.70) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL24390900 | 0.90 | BCHE (0.74) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL13144547 | 0.89 | BCHE (0.82) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL14640874 | 0.89 | BCHE (0.56) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL13595162 | 0.88 | BCHE (0.63) | BCHEACHEFAAHABCC4CACNA1F | |
| SCHEMBL14539983 | 0.88 | BCHE (0.70) | BCHEACHEFAAHABCC4CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016759-A1 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | CORIUM, LLC | 2024-01-18 | — | — | US | disclosed |
| US-20180185298-A1 | Transdermal Adhesive Composition Comprising A Poorly Soluble Therapeutic Agent | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2018-07-05 | — | — | US | disclosed |
| US-9993466-B2 | Donepezil transdermal delivery system | CORIUM INTERNATIONAL, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20180028462-A1 | DONEPEZIL TRANSDERMAL DELIVERY SYSTEM | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180028512-A1 | DONEPEZIL TRANSDERMAL DELIVERY SYSTEM | COLUMBUS INVESTMENT HOLDINGS SA (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20170290780-A1 | TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | ICURE PHARMACEUTICAL INC. (KR) | 2017-10-12 | — | — | US | disclosed |
| US-9682037-B2 | Non-mucoadhesive film dosage forms | APR APPLIED PHARMA RESEARCH SA (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20160184439-A1 | ORALLY DISINTEGRATING FILM PREPARATION CONTAINING DONEPEZIL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR | SEOUL PHARMA. CO., LTD. (KR) | 2016-06-30 | — | — | US | disclosed |
| US-8999994-B2 | Derivatives of propargylamine having neuroprotective capacity for the treatment of Alzheimer's and Parkinson's diseases | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2015-04-07 | — | — | US | disclosed |
| US-20150025112-A1 | ORALLY DISINTEGRATING TABLET FORMULATIONS OF DONEPEZIL | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-01-22 | — | — | US | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| WO-2006107859-A2 | DIHYDROPYRIDINE COMPOUNDS FOR NEURODEGENERATIVE DISEASES AND DEMENTIA | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006107860-A2 | DIHYDROPYRIDINE COMPOUNDS AND COMPOSITIONS FOR HEADACHES | EISAI CO., LTD. (JP) | 2006-10-12 | — | — | WO | disclosed |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | EISAI CO., LTD. (JP) | 2006-08-03 | — | — | US | disclosed |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2005087226-A1 | CADASIL TREATMENT WITH CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2005-09-22 | — | — | WO | disclosed |
| WO-2004034963-A2 | METHODS AND COMPOSITIONS USING CHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003092606-A2 | CHOLINESTERASE INHIBITORS TO PREVENT INJURIES CAUSED BY CHEMICALS | EISAI CO., LTD. (JP) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003024450-A1 | METHODS FOR TREATING PRION DISEASES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | BCHE 2/4885ACHE 1/4885FAAH 510/4885 |
| US-20160184439-A1 | ORALLY DISINTEGRATING FILM PREPARATION CONTAINING DONEPEZIL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR | ACHE, SI, ALG1 | BCHE 21/4885ACHE 1/4885FAAH 2983/4885 |
| US-20180028512-A1 | DONEPEZIL TRANSDERMAL DELIVERY SYSTEM | BCHE, ACHE, CHAT | BCHE 1/4885ACHE 2/4885FAAH 317/4885 |
| US-20060135507-A1 | Therapeutic agent for overactive bladder involved in aging | ACHE, BPHL, GLA | BCHE 9/4885ACHE 1/4885FAAH 332/4885 |
| US-20150025112-A1 | ORALLY DISINTEGRATING TABLET FORMULATIONS OF DONEPEZIL | SI, ACHE, HNMT | BCHE 22/4885ACHE 2/4885FAAH 1631/4885 |
| US-20060172992-A1 | Therapeutic agent for overactive bladder resulting from cerebral infarction | ACHE, CHAT, BCHE | BCHE 3/4885ACHE 1/4885FAAH 412/4885 |
| US-20180185298-A1 | Transdermal Adhesive Composition Comprising A Poorly Soluble Therapeutic Agent | CDH1, CD44, COL14A1 | BCHE 243/4885ACHE 81/4885FAAH 1489/4885 |
| US-20240016759-A1 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | CD69, CUTA, PGRMC2 | BCHE 2211/4885ACHE 2045/4885FAAH 1389/4885 |
| US-20180028462-A1 | DONEPEZIL TRANSDERMAL DELIVERY SYSTEM | BCHE, ACHE, CHAT | BCHE 1/4885ACHE 2/4885FAAH 317/4885 |
| US-20170290780-A1 | TRANSDERMAL COMPOSITION CONTAINING DONEPEZIL AS ACTIVE INGREDIENT | PSEN1, ACHE, CUTA | BCHE 41/4885ACHE 2/4885FAAH 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.